Sandro Anchisi
Wallis
19 Papers
121 Citations
Sandro Anchisi is an academic researcher from Wallis. The author has contributed to research in topics: Medicine & Bevacizumab. The author has an hindex of 7, co-authored 15 publications.
Chat about Author
Papers
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
G. Pesce,Dirk Klingbiel,Karin Ribi,Abderahim Zouhair,Roger von Moos,Marc Schlaeppi,Clemens B. Caspar,Natalie Fischer,Sandro Anchisi,Solange Peters,Richard Cathomas,Jürg Bernhard,Nina M. Kotrubczik,G. D'Addario,Christiane Pilop,Damien C. Weber,Stephan Bodis,Miklos Pless,M. Mayer,Roger Stupp +19 more
TL;DR: In this article, two combined modality regimens with novel agents with single agent activity and radiosensitizing properties were explored, and the primary endpoint was overall survival, with quality of life and cognitive function as secondary end-points.
80
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz,Martin Bigler,Roger von Moos,Jürg Bernhard,Klazien Matter-Walstra,Andreas Wicki,Khalil Zaman,Sandro Anchisi,Marc Küng,Kyung-Jae Na,Daniela Bärtschi,Markus Borner,Tamara Rordorf,Daniel Rauch,A. Müller,Thomas Ruhstaller,Marcus Vetter,Andreas Trojan,U Hasler-Strub,Richard Cathomas,Ralph Winterhalder +20 more
TL;DR: This trial failed to meet its primary endpoint of a reduced rate of prespecified grade 3–5 AEs with metronomic bevacizumab, cyclophosphamide and capecitabine, and other secondary efficacy endpoints were not significantly different between study arms.
48
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06).
Dieter Koeberle,Daniel Betticher,Roger von Moos,Daniel Dietrich,Peter Brauchli,Daniela Baertschi,Klazien Matter-Walstra,Ralph Winterhalder,Markus Borner,Sandro Anchisi,Peter Moosmann,Attila Kollár,Piercarlo Saletti,Arnaud Roth,M. Frueh,Marc Kueng,R. A. Popescu,Sabina Schacher,Viviane Hess,Richard Herrmann +19 more
TL;DR: Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer patients and whether no continuation is non-inferior to continu...
33
Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).
Silke Gillessen,Roger Anton Fredy Von Moos,Stefanie Hayoz,Hanne Hawle,Richard Cathomas,Christian Rothermundt,Sandro Anchisi,Andreas Mueller,Tobias Wehrhahn,Henning Burmeister,Susanna Stoll,Anna Planas Lladó,Markus Borner,Augusto Pedrazzini,Urs Sebastian Huber-Tribolet,Pierre Oliver Bohanes,Ralph Winterhalder,Andrea Corinne Fuhrer,Corinne Schaer,Arnoud J. Templeton +19 more
TL;DR: In this trial nearly 30% of all men treated with DN experienced HC in the q4w induction phase despite mandatory supplementation of calcium and ViD and measurement of Ca, considerably higher than reported in the registration trials of DN.
17
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
Christoph Rochlitz,Roger von Moos,Martin Bigler,Khalil Zaman,Sandro Anchisi,Marc Küng,Kyung Jae Na,Daniela Baertschi,Markus Borner,Tamara Rordorf,Daniel Rauch,Andreas Mueller,Thomas Ruhstaller,Marcus Vetter,Juerg Bernhard,Andreas Trojan,U Hasler-Strub,Richard Cathomas,Ralph Winterhalder +18 more
TL;DR: The aim of this study was to demonstrate decreased toxicity of metronomic chemotherapy/bevacizumab when compared to paclitaxel/ bevacIZumab as first-line treatment in patients with HER2-negative advanced breast cancer.
14